Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPriority Health Employer Group Pharmacy Prior Auth…
    Ask Trek AI about this page
    Currentpriority healthPolicy N/A

    Employer Group Pharmacy Prior Authorization Criteria (partial)

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document defines prior authorization requirements and coverage criteria for pharmacy drugs under Priority Health employer group plans; it is intended for providers submitting pharmacy prior authorization requests and for plan administrators referencing the Approved Drug List (ADL).

    Policy Summary
    Payerpriority health
    PolicyEmployer Group Pharmacy Prior Authorization Criteria (partial)
    Policy CodePolicy N/A
    Change TypeAdministrative (no material clinical changes)
    Effective DateJul 20, 2026
    Last ReviewJul 20, 2026
    Next Review DateJul 20, 2026
    Key ActionComplete the Employer Group & MyPriority Plans Pharmacy (NonOncology) drug request form or submit an electronic prior authorization (ePA) when requesting prior authorization.
    SourceLink
    3drug-specific entries in excerpt
    120opioid MEqD limit
    12 monthstypical approval duration
    1 monthActhar approval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Hgb & ferritin
    Accrufer required labs

    Coverage Criteria — Drug- and Indication-specific Rules

    Opioid Quantity/Dose Limit Exception

    Covered when ALL of the following are met for requests exceeding 120 MEqD/day:

    Opioid dose exception requirements: Patients are limited to a total of 120 MEqD per day. For requests that exceed this amount the following are required: an opioid treatment agreement; documented diagnosis of chronic pain due to a medical condition; documented dose taper or documented rationale for not attempting taper; routine evaluation of pain management and function using validated tools showing sustained improvement; trial of non-drug therapy in the last 18 months or documentation that non-drug therapy is contraindicated; concurrent use of non-opioid medications unless contraindicated; documentation supporting clinical appropriateness and safety when concurrently using benzodiazepines, sedative-hypnotics, barbiturates, or other potentially harmful combinations; and patient education on naloxone; AND individual drug limits, step therapy, and utilization management may also apply; authorization up to 12 months.>120 MEqD/day

    Duration up to 12 months

    Accrufer (ferric maltol)

    Covered when ALL of the following are met:

    Accrufer initial therapy criteria: Diagnosis of iron deficiency anemia; documentation of baseline (pre-treatment) hemoglobin and ferritin levels; inadequate response to two different generic oral iron therapies.

    See intolerance management options (e.g., every-other-day dosing, dietary/administration changes) if prior oral iron intolerant

    Accrufer continuation criteria: Documentation of improvement in condition from baseline (for example, improved tolerance and/or increased hemoglobin and ferritin levels).

    Duration of approval up to 12 months

    Acthar: Initial therapy

    Covered when ALL of the following are met

    Acthar initiation: Patient has a diagnosis of infantile spasms AND is less than 2 years of age.

    Duration of approval: 1 month (up to 75 units/m2 twice daily for two weeks, then taper for two weeks)

    Acthar: Not medically necessary for listed corticosteroid‑responsive conditions

    Acthar NMN indications: Use for listed corticosteroid‑responsive conditions (e.g., acute MS exacerbations; rheumatic disorders; collagen diseases; dermatologic diseases such as Stevens‑Johnson syndrome; allergic, ophthalmic, respiratory diseases; edematous states) is not considered medically necessary as it has not been proven more effective than corticosteroids.

    Adalimumab: General and indication‑specific criteria

    Covered when ALL of the General Criteria AND the Specific Criteria for the treated diagnosis are met

    General Criteria: Prescriber is a specialist or has consulted with a specialist for the condition being treated; adalimumab will not be covered in combination with another biologic drug.

    If criteria not met, prescriber must provide explanation for exception

    Crohn's disease specific: Diagnosis of moderate to severe Crohn's disease AND trial and failure or intolerance/contraindication to adequate conventional therapy (e.g., steroids for 7 days, azathioprine ≥2 months).
    Ulcerative colitis specific: Diagnosis of moderate to severe ulcerative colitis AND trial and failure or intolerance/contraindication to adequate conventional therapy (e.g., steroids for 7 days, azathioprine ≥2 months).
    Uveitis specific: Noninfectious intermediate, posterior or panuveitis AND trial of one other agent (e.g., periocular/intraocular/systemic corticosteroids or immunosuppressives such as methotrexate, mycophenolate mofetil, cyclosporine, azathioprine, cyclophosphamide).

    Adbry: Initial therapy

    Covered when ALL of the following are met

    Adbry initiation: Prescriber is a specialist or has consulted with a specialist AND patient has moderate to severe atopic dermatitis AND patient has tried ONE of: a medium‑to‑high potency topical corticosteroid for ≥3 months OR a topical calcineurin inhibitor (tacrolimus or pimecrolimus) for ≥3 months.3 months

    Duration of approval: 12 months; not to be used in combination with other biologic therapy

    Adbry continuation: For continuation, patient must have a positive clinical response (e.g., reduction in BSA affected from baseline, reduction in pruritus severity and flares, improvement in activities of daily living).

    Duration of approval: 12 months

    Adbry initial and continuation

    Covered when ALL of the following are met for atopic dermatitis:

    Prescriber requirement: Prescriber is a specialist or has consulted with a specialist for the condition being treated.
    Diagnosis and severity: Patient has moderate to severe atopic dermatitis.
    Prior topical therapy: Patient has tried ONE of: a medium to high potency topical corticosteroid for at least 3 months OR a topical calcineurin inhibitor (tacrolimus or pimecrolimus) for at least 3 months.3 months
    Continuation response: For continuation, patient must have a positive clinical response (e.g., reduction in BSA, reduction in pruritus, improved ADL).

    Duration of approval: 12 months; not to be used in combination with other biologic drug therapy.

    PCSK9 inhibitors initial

    Covered when ALL of the following are met for hypercholesterolemia/HeFH/HoFH or ASCVD:

    Prior statin trial: Patient has tried one high-intensity statin (atorvastatin ≥40 mg or rosuvastatin ≥20 mg) for a minimum of 8 weeks continuously and LDL-C remains above goal.8 weeks
    No concurrent agents: Not to be used in combination with another PCSK9 inhibitor, Leqvio, Nexletol/Nexlizet.
    Non-preferred agent requirements: For non-preferred product, prescribed by a cardiologist/endocrinologist/board-certified lipidologist AND trial and failure or intolerance to preferred product AND continuation/additional statin therapy as appropriate.

    Acute antimigraine agents initial

    Covered when ALL of the following are met for acute migraine treatment:

    Diagnosis: Patient has a diagnosis of migraine with or without aura.
    Age: Patient is at least 18 years of age.>=18 years
    Prior triptan trial: Have tried one triptan (e.g., sumatriptan, rizatriptan, naratriptan, zolmitriptan).
    Non-preferred agent requirement: For non-preferred acute branded products, trial and failure or intolerance to the preferred product (Ubrelvy) AND an additional triptan are required.

    Duration of approval typically 12 months; branded acute agents are not to be combined with one another.

    Initial coverage — migraine preventive

    Covered when ALL of the following are met for migraine headache requests

    Migraine diagnosis: Patient has a diagnosis of migraine with or without aura.
    Frequency: Patient has at least four migraine days per month.>=4 days/month
    Prior medications: Patient has tried any two of the following oral medications: antidepressants (e.g., amitriptyline, nortriptyline); beta blockers (e.g., propranolol, metoprolol, timolol); anti-epileptics (e.g., valproate, topiramate).

    Non-preferred antimigraine

    Covered when ALL of the following are met for non-preferred antimigraine agents

    Preferred biologic failures: Trial and failure, or intolerance/contraindication to Aimovig, Emgality, and Ajovy for 3 continuous months each and not achieving adequate reduction in migraines.3 months each

    Applies to non-preferred drug product

    Initial coverage — cluster headache (Emgality only)

    Covered when ALL of the following are met for episodic cluster headache (Emgality only)

    Age: Patient is at least 18 years of age.>=18 years
    Diagnosis: Patient has a diagnosis of episodic cluster headache.
    Prior treatments: Has tried and failed at least 2 of the following: injectable triptan (sumatriptan), intranasal triptan (sumatriptan or zolmitriptan), oxygen therapy, verapamil, topiramate, valproate.failures of >=2 options

    Initial coverage — antiretroviral for multidrug-resistant HIV-1

    Covered when ALL of the following are met for heavily treatment-experienced HIV-1 adults

    Diagnosis: Patient has a diagnosis of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.
    Virologic failure: Confirmed failure of current antiretroviral regimen with baseline HIV-1 RNA at least 400 copies/mL.>=400 copies/mL
    Resistance profile: No viable ARV combination therapy available as documented resistance to two or more agents from three of four main ARV classes.
    Combination use: Requested agent is to be used in combination with an optimized background antiretroviral regimen with documentation of full viral sensitivity to at least one other ARV agent.

    Continuation of therapy

    Continuation of coverage requires evidence of clinical benefit

    Migraine effectiveness: Demonstrate effectiveness defined as more than 50% reduction in monthly migraine days.>50% reduction
    Cluster effectiveness: Demonstrate significant decrease in frequency and/or intensity of cluster headaches and be in a current cluster period (Emgality only).

    Continuation of antiretroviral therapy

    Continuation of antiretroviral coverage requires response and maintenance

    Viral response: Patient has achieved clinically significant viral response to therapy.
    Background regimen: Patient has continued to take an optimized background antiretroviral regimen.

    Arcalyst — Initial Therapy

    Covered when ALL of the following are met

    Arcalyst - indication: Patient has diagnosis of CAPS (including FCAS and MWS) in adults and children ≥12 years OR diagnosis of DIRA in adults and children ≥10 kg OR diagnosis of recurrent pericarditis with risk reduction in adults and children ≥12 years.

    Arcalyst not covered in combination with another biologic; prescriber must meet General and Specific Criteria or provide rationale for exception

    Arikayce — Initial and Continuation Therapy

    Covered when ALL of the following are met

    Arikayce - diagnosis: Diagnosis of Mycobacterium avium complex (MAC) lung disease with supporting sputum culture submitted to Priority Health.

    Sputum culture supporting diagnosis must be submitted; prescribed by/with infectious disease specialist

    Arikayce - prior therapy failure: Failure to obtain a negative sputum culture after a minimum of 6 consecutive months of a multidrug background regimen for MAC (e.g., clarithromycin/azithromycin, rifampin, ethambutol); AND therapy used as part of a multidrug regimen (not as single agent).6 months

    Must be part of a multidrug regimen; not approved as single agent; prescribed by or in consultation with an infectious disease specialist

    Arikayce - continuation: For continuation: documentation of a negative sputum culture within the last 30 days, compliance, tolerability, and physician-assessed response to treatment.negative sputum culture within 30 days

    Benlysta — Initial and Continuation Therapy

    Covered when ALL of the following are met (separate paths for SLE and lupus nephritis)

    Benlysta - indication options: Active, autoantibody-positive SLE OR biopsy-proven lupus nephritis Class III–V.

    Patient must be ≥5 years for both indication options

    Benlysta - SLE requirements: For active, autoantibody-positive SLE: patient ≥5 years; autoantibody-positive (ANA ≥1:80 OR anti-dsDNA ≥30 IU/mL); active SLE demonstrated by SELENA‑SLEDAI score >6 while on standard therapy for ≥12 weeks.SELENA‑SLEDAI >6; ANA ≥1:80 OR anti-dsDNA ≥30 IU/mL; 12 weeks on standard therapy

    Continuation requires meeting 3 of 6 specified response criteria

    Benlysta - lupus nephritis requirements: For biopsy‑proven lupus nephritis Class III–V: patient ≥5 years; autoantibody‑positive (ANA ≥1:80 OR anti‑dsDNA ≥30 IU/mL); active renal disease requiring standard therapy; and eGFR ≥30 mL/min/1.73m2.eGFR >=30 mL/min/1.73m2

    Benlysta — Initial Therapy

    Covered when ALL of the following are met

    Benlysta initial criteria: Patient is at least 5 years of age; autoantibody‑positive (ANA ≥1:80 OR anti‑dsDNA ≥30 IU/mL); active SLE as demonstrated by SELENA‑SLEDAI >6 while on standard therapy for ≥12 weeks. Lupus nephritis branch includes similar antibody criteria, active renal disease, and eGFR ≥30 mL/min/1.73m2.

    Initial approval duration: 6 months

    Benlysta — Continuation Therapy

    Continuation covered when patient meets 3 of the following 6 response criteria for active, autoantibody-positive SLE

    Benlysta continuation criteria: Meet 3 of 6 clinical/lab/assessment response criteria: SELENA‑SLEDAI reduction ≥4 at 30 days; Physician Global Assessment showing no disease progression vs baseline; BILAG A=0 and B≤1 in last 4 weeks; reduction in steroid dose; negative seroconversion or ≥20% reduction in autoantibody levels; free of significant clinical flares requiring steroid boost.3 of 6

    For lupus nephritis continuation: UPCR <=0.7, eGFR criteria, and no rescue therapy use

    Besremi — Initial and Continuation Therapy

    Covered when ALL of the following are met

    Besremi initial criteria: Diagnosis of high‑risk polycythemia vera with supporting documentation; patient ≥18 years; prescribed by or in consultation with a hematologist/oncologist; trial and failure of hydroxyurea AND pegylated interferon‑alfa 2a; ECOG 0–2; eGFR ≥30 mL/min/1.73m2.

    Supporting documentation must be submitted

    Besremi continuation criteria: Patient has positive clinical response evidenced by disease stability or improvement.

    Duration of approval: 12 months

    Bimzelx — Initial Therapy (by indication)

    Covered when ALL General Criteria plus indication-specific criteria are met

    Bimzelx general: Prescriber is a specialist or has consulted with a specialist; Bimzelx will not be covered in combination with another biologic drug.

    Exceptions require prescriber explanation

    Plaque psoriasis specifics: Tried one traditional non‑biologic systemic ≥3 months AND tried at least TWO of (adalimumab, Cosentyx, Enbrel, Otezla/XR, ustekinumab) each ≥3 months.>=3 months
    Hidradenitis suppurativa specifics: Tried one other agent for HS AND tried at least TWO of (Cosentyx, adalimumab, infliximab) each ≥3 months.>=3 months
    Ankylosing spondylitis specifics:

    Cablivi — Initial and Continuation Therapy

    Covered when ALL of the following are met

    Cablivi initial: Diagnosis of acquired TTP with thrombocytopenia and microangiopathic hemolysis; patient ≥18 years; to be administered in addition to plasma exchange and immunosuppressive therapy and continued for 30 days after plasma exchange ends.

    Initial approval duration 30 days with quantity limit 31 vials/30 days

    Cablivi continuation: Patient has received Cablivi with plasma exchange and immunosuppression during plasma exchange and for 30 days beyond; has signs of persistent underlying disease such as suppressed ADAMTS13 activity; and treatment may be extended for a maximum of 28 days.max 28 days continuation

    Continuation quantity limit 28 vials per 28 days

    Cablivi continuation

    Cablivi — Continuation of coverage

    Cablivi continuation requirements: Patient has received Cablivi in combination with plasma exchange and immunosuppressive therapy during plasma exchange and for 30 days beyond the last plasma exchange; AND patient has signs of persistent underlying disease such as suppressed ADAMTS13 activity levels; AND treatment will be extended for a maximum of 28 days.max 28 days continuation

    Continuation quantity limits apply

    Initial Therapy — Cardiac myosin inhibitors initial coverage

    Cardiac myosin inhibitors — Initial coverage

    Initial therapy for Camzyos/Myqorzo: Patient has symptomatic NYHA class II or III obstructive hypertrophic cardiomyopathy; patient is at least 18 years of age; left ventricular ejection fraction ≥55%; prescribed by or in consultation with a cardiologist; and trial and failure, intolerance, or contraindication to BOTH a beta blocker (e.g., metoprolol) AND a calcium channel blocker (e.g., verapamil, diltiazem).initial approval 6 months

    Initial approval 6 months; continuation 12 months

    Continuation Therapy — Cardiac myosin inhibitors continuation coverage

    Cardiac myosin inhibitors — Continuation coverage

    Continuation therapy for Camzyos: Documentation of positive clinical response compared to baseline (e.g., symptom improvement, NT‑proBNP reduction, decreased dyspnea); AND improvement of pVO2 by at least 1.5 mL/kg/min PLUS at least one NYHA class reduction OR at least a 3 mL/kg/min pVO2 improvement with stable NYHA class.continuation approval 12 months

    Continuation approval duration 12 months

    Carglumic acid — Initial and continuation coverage

    Carglumic acid — Initial and continuation coverage

    Carglumic acid criteria: Patient has a diagnosis of N‑acetylglutamate synthase (NAGS) deficiency; AND has acute or chronic hyperammonemia; AND for continuation, clinical documentation of disease stability or improvement must be provided.approval up to 12 months

    Duration up to 12 months

    Cayston - Initial and Continuation Therapy

    Covered when ALL of the following are met

    Cayston initial criteria: Patient has a diagnosis of cystic fibrosis with documentation of an approved CF ICD‑10 code within the last 12 months; patient is at least 7 years of age; confirmation of Pseudomonas aeruginosa in airway cultures (copy of positive sputum culture); AND susceptibility results showing aztreonam is the only inhaled antibiotic the Pseudomonas is sensitive to OR prior tobramycin inhalation solution use produced clinically significant adverse reaction or unsatisfactory response OR contraindication/intolerance to tobramycin inhalation solution OR culture shows resistance to tobramycin.

    Initial approval 6 months; dosing cycles 28 days on/28 days off

    Cayston continuation criteria: Continues to require treatment of Pseudomonas aeruginosa infection AND documentation of stabilization or improvement by pulmonologist or CF specialist.

    Continuation approvals 12 months; dosing cycles 28 days on/28 days off

    Cholbam - Initial and Continuation Therapy

    Covered when ALL of the following are met

    Cholbam initial criteria: Patient has a diagnosis of bile acid synthesis disorder due to single enzyme defects (SED) or peroxisomal disorder (PD); provide a serum very long chain fatty acid (VLCFA) value; and provide baseline liver function tests.
    Cholbam continuation criteria: Body weight increased by 10% or stable at least the 50th percentile; AND ALT or AST <50 U/L or baseline levels reduced by 80%; AND total bilirubin ≤1 mg/dL; AND no evidence of cholestasis on liver biopsy.

    Duration: 12 months

    Cibinqo - Initial and Continuation Therapy

    Covered when ALL of the following are met

    Cibinqo initial criteria: Prescriber is a specialist or has consulted with a specialist; patient has moderate to severe atopic dermatitis; patient has tried ONE medium to high potency topical corticosteroid for ≥3 months OR one topical calcineurin inhibitor for ≥3 months; AND patient has tried at least TWO of the following systemic/biologic agents: Dupixent, Adbry, Nemluvio each for ≥3 months.3 months

    Duration of approval 12 months; not covered in combination with other biologic therapy

    Cibinqo continuation: Have a positive clinical response (e.g., reduction in BSA affected from baseline, reduction in pruritus severity and flares, improvement in ADL).

    Cibinqo (atopic dermatitis)

    Covered when ALL of the following are met for atopic dermatitis:

    Cibinqo initiation: Prescriber is a specialist or has consulted a specialist; patient has moderate to severe atopic dermatitis; patient has tried ONE medium to high potency topical corticosteroid for ≥3 months OR one topical calcineurin inhibitor for ≥3 months; and patient has tried at least TWO of: Dupixent, Adbry, Nemluvio each for ≥3 months.3 months

    Duration of approval 12 months; Cibinqo not covered with other biologic therapy; provide rationale for non‑FDA uses if requested

    Cimzia (certolizumab) initiation

    Covered when ALL of the General Criteria plus the Specific Criteria for the treatment diagnosis are met:

    Cimzia general: Prescriber is a specialist or has consulted with a specialist. Cimzia will not be covered in combination with another biologic drug.

    If criteria not met, prescriber must provide explanation

    Ankylosing spondylitis: Patient has tried at least TWO of: adalimumab, Cosentyx, Enbrel, Xeljanz/XR each ≥3 months.>=3 months
    nr-axSpA: Patient has objective signs of inflammation (elevated CRP and/or MRI sacroiliitis).
    Crohn disease: Diagnosis of moderate to severe Crohn disease; tried and failed/intolerant to adequate conventional therapy (e.g., steroids 7 days, azathioprine ≥2 months); and tried at least ONE of: adalimumab, infliximab, ustekinumab ≥3 months.

    Cobenfy (xanomeline/trospium)

    Covered when ALL of the following are met for schizophrenia:

    Cobenfy initiation: Diagnosis of schizophrenia; patient is ≥18 years; tried and failed or intolerant/contraindicated to two atypical antipsychotics used for at least 28 days each; prescriber is a specialist or has consulted with a specialist.

    Duration of approval 12 months

    Cosentyx (secukinumab) initiation

    Covered when ALL of the General Criteria plus Specific Criteria for the diagnosis are met:

    Cosentyx general: Prescriber is a specialist or has consulted with a specialist. Cosentyx will not be covered in combination with another biologic drug.

    Provide rationale for off‑label uses

    Plaque psoriasis: Patient has tried one traditional non‑biologic systemic agent (e.g., methotrexate, cyclosporine, acitretin) for ≥3 months.>=3 months
    Psoriatic arthritis: Patient has tried at least one traditional non‑biologic systemic agent for ≥3 months.>=3 months
    Ankylosing spondylitis:

    Cosentyx: Initial Therapy

    Cosentyx is covered when ALL of the following are met for the requested indication:

    Cosentyx General and Indication-specific Criteria: Prescriber is a specialist or has consulted with a specialist; For Plaque Psoriasis: trial of one traditional non‑biologic systemic agent ≥3 months; For Psoriatic Arthritis: trial of at least one traditional non‑biologic systemic agent ≥3 months; For Ankylosing Spondylitis: meets General Initiation Criteria; For nr‑axSpA: objective signs of inflammation (elevated CRP and/or MRI sacroiliitis); For Hidradenitis Suppurativa: tried at least one other agent (e.g., intralesional/oral corticosteroids, systemic antibiotics, isotretinoin).

    Cosentyx not covered in combination with another biologic

    Crenessity: Initial and Continuation Therapy

    Crenessity is covered when ALL of the following are met:

    Crenessity Initial Criteria: Diagnosis of classic CAH confirmed by genetic testing showing 21‑hydroxylase deficiency (21OHD); patient ≥4 years; stable on current glucocorticoid dose for ≥1 month and receiving >13 mg/m2/day hydrocortisone equivalents; demonstrated inability to lower GC dose by laboratory or clinical evidence; and medical necessity to lower GC dose (e.g., uncontrolled hypertension, diabetes, weight gain, bone mineral density loss); prescriber is a specialist or has consulted a specialist.

    Continuation requires reduced daily glucocorticoid dose from baseline

    Crenessity Continuation Criteria: Positive clinical response evidenced by reduced daily glucocorticoid dose from baseline.

    Duration of approval: Initial 6 months; Continuation 12 months

    Cresemba: Initial and Continuation Therapy

    Cresemba is covered when ALL of the following are met:

    Cresemba Initial Criteria: Diagnosis of invasive aspergillosis or invasive mucormycosis; tried and failed or intolerant/contraindicated to voriconazole or itraconazole; prescriber is a specialist or has consulted a specialist.

    Initial approval 3 months; continuation 12 months

    Cresemba Continuation Criteria: Positive clinical response evidenced by disease stability or improvement.

    CFTR modulators — Initial Therapy

    Covered when ALL of the following are met for CFTR modulators

    CFTR modulators initiation: Patient has a diagnosis of cystic fibrosis with documentation of an approved ICD‑10 code within the last 12 months; AND requested formulation matches FDA label for patient age (e.g., Trikafta listed among CFTR modulators).

    Dalfampridine ER — Initial and Continuation Therapy

    Covered when ALL of the following are met for dalfampridine ER (Ampyra)

    Dalfampridine ER initiation: Diagnosis of multiple sclerosis; receiving immunomodulatory therapy when indicated; age 18–70 years; significant continuous walking impairment that impairs daily activities despite optimal MS treatment; patient does not require a wheelchair (bilateral assistance acceptable if patient can walk 20 meters without resting); baseline T25FW completed within 8–45 seconds OR EDSS ≥4.5 and <7.

    Initial approval 6 months

    Dalfampridine ER continuation: Maintain 85% adherence by fill history; functional improvement with increased speed of ambulation allowing instrumental activities; at least 20% improvement in T25FW from pre‑treatment baseline.>=20% improvement

    Continuation approval 12 months; exclusions apply (spinal cord injury, myasthenia gravis, demyelinating peripheral neuropathies, Alzheimer disease, Lambert Eaton)

    Daybue (trofinetide) — Initial and Continuation Therapy

    Covered when ALL of the following are met for Daybue (trofinetide)

    Daybue initiation: Diagnosis of classic/typical Rett syndrome with MECP2 gene mutation (supporting documentation); baseline Rett syndrome severity documented using an objective tool (e.g., CGI, RSBQ, MBA); in‑depth behavioral assessment by neurologist/geneticist/developmental pediatrician; patient age ≥2 years; prescriber is a specialist or has consulted a specialist.

    Daybue not covered for atypical or variant Rett syndrome; initial approval 3 months

    Daybue continuation: Documentation of positive clinical response evidenced by improvement in disease severity using an objective measure or tool (e.g., CGI, RSBQ, MBA).

    Continuation approval 3 months

    Initial Therapy — Diacomit

    Covered when ALL of the following are met

    Diacomit initial: Patient has a diagnosis of Dravet syndrome and will use Diacomit as adjunctive treatment for seizures; patient is at least 2 years of age; will use in combination with clobazam; and has had trial and failure with valproate and clobazam.

    Diacomit not supported as monotherapy

    Initial and Continuation Therapy — Droxidopa

    Covered when ALL of the following are met

    Droxidopa initial: Diagnosis of symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure, dopamine beta‑hydroxylase deficiency, or non‑diabetic autonomic neuropathy; other causes excluded; patient has tried at least two listed non‑pharmacologic interventions; prescribed by or in consultation with a cardiologist, neurologist, or nephrologist; and trial and failure (≥30 days), intolerance, or contraindication to both midodrine and fludrocortisone.

    Initial approval 3 months; continuation 6 months with documentation of clinical response and objective BP improvement

    Droxidopa continuation: Documentation of positive clinical response to droxidopa therapy; sustained decrease in dizziness since initiation; maintained increase in systolic and diastolic BP within 3 minutes of standing since initiation.

    Continuation approval duration: 6 months

    Initial Therapy — Dupixent (by indication)

    Covered when ALL indication-specific criteria are met

    Dupixent for Atopic Dermatitis: Patient has moderate to severe atopic dermatitis AND has tried one medium to high potency topical corticosteroid for ≥3 months OR one topical calcineurin inhibitor for ≥3 months.3 months
    Dupixent for Asthma: Eosinophilic asthma confirmed by peripheral blood eosinophils >150 cells/mcL in past 12 months OR daily oral corticosteroid dependence; AND patient has tried one inhaled corticosteroid plus one additional controller; AND had at least one asthma exacerbation in prior year.>150 cells/mcL
    Dupixent for COPD: Diagnosis of moderate‑to‑severe COPD (FEV1/FVC <0.7 AND FEV1 30–70%); eosinophilic phenotype with peripheral eosinophils >300 cells/mcL in past 12 months; symptomatic COPD (mMRC ≥2 or CAT ≥10); trial and failure of LABA/LAMA or triple therapy for ≥3 months; will continue LABA/LAMA or triple therapy with Dupixent; and specified exacerbation history; patient is a current non‑smoker.

    Dupixent — COPD Initial Therapy

    Covered when ALL of the following are met for moderate-to-severe COPD:

    Dupixent COPD initiation: Patient has diagnosis of moderate‑to‑severe COPD (FEV1/FVC <0.7 AND FEV1 30–70%); eosinophilic phenotype confirmed by peripheral blood eosinophils >300 cells/mcL in past 12 months; symptomatic COPD (mMRC ≥2 or CAT ≥10); tried and failed LABA/LAMA or triple therapy after ≥3 months; will continue LABA/LAMA or triple therapy with Dupixent; and has required exacerbation history; patient is a current non‑smoker.see thresholds

    Duration of approval 12 months; continuation requires decreased symptoms/exacerbations vs baseline

    Dupixent — Continuation Therapy

    Continuation of coverage requires evidence of clinical response specific to the indication:

    Continuation evidence: For each indication, demonstrate positive clinical response (examples: AD—reduced BSA/pruritus; asthma—reduced exacerbations/decreased OCS use; CRSwNP—improved nasal symptoms; COPD—decreased symptoms/exacerbations and continued LABA/LAMA with Dupixent; prurigo nodularis—adherence and WI‑NRS/nodule reduction; EoE—histologic remission <=6 eos/hpf and DSQ improvement; chronic urticaria—reduction in urticaria symptoms).varies by indication

    See specific indication nodes for required measures

    Prurigo Nodularis — Initial Therapy

    Covered when ALL of the following are met for prurigo nodularis:

    Prurigo nodularis initiation: Moderate to severe disease (WI‑NRS ≥7 and ≥20 nodular lesions); tried one medium‑to‑high potency topical corticosteroid for ≥3 months; tried one topical calcineurin inhibitor for ≥3 months.WI‑NRS >=7; >=20 nodules

    Continuation requires adherence and positive clinical response

    Eosinophilic Esophagitis — Initial Therapy

    Covered when ALL of the following are met for eosinophilic esophagitis (EoE):

    EoE initiation: EoE confirmed by biopsy (≥15 intraepithelial eos/hpf); failed dietary modification; failed one PPI for ≥2 months; failed one topical corticosteroid (e.g., fluticasone, budesonide) for ≥2 months.>=15 eos/hpf

    Continuation requires histologic remission ≤6 eos/hpf and clinical response

    Chronic Urticaria — Initial Therapy

    Covered when ALL of the following are met for chronic urticaria:

    Chronic urticaria initiation: Patient is at least 12 years of age; first try two or more H1 antihistamines OR one H1 antihistamine plus one or more of H2 antihistamine, oral corticosteroid, or leukotriene modifier.age >=12

    Continuation requires positive clinical response

    Bullous Pemphigoid — Initial Therapy

    Covered when ALL of the following are met for moderate to severe bullous pemphigoid:

    Bullous pemphigoid initiation: Moderate to severe disease (BPDAI ≥24 and weekly average Peak Pruritus NRS =4); tried one medium‑to‑high potency topical corticosteroid for ≥3 months; tried one oral corticosteroid for ≥3 months; tried one traditional non‑biologic systemic agent for ≥3 months.BPDAI >=24; Peak Pruritus NRS >=4

    Continuation requires adherence and positive clinical response

    Dyspareunia Agents — Initial Therapy

    Covered when ALL of the following are met for dyspareunia due to vulvovaginal atrophy:

    Dyspareunia agents initiation: Diagnosis of moderate to severe dyspareunia caused by vulvovaginal atrophy; plan documents include sexual dysfunction rider; documented trial with OTC vaginal lubricant for ≥90 days; documented trial of a vaginal estrogen product for ≥90 days.>=90 days trials

    Preferred agents listed: Imvexxy, Intrarosa

    Enbrel — General and Indication-specific Criteria

    Enbrel is covered when General Initiation Criteria and indication-specific criteria are met:

    Enbrel general: Prescriber is a specialist or has consulted with a specialist for the condition. Enbrel will not be covered in combination with another biologic drug. For each indication, patient must have tried specified traditional non‑biologic systemic agents for ≥3 months unless exceptions apply.>=3 months

    Examples: plaque psoriasis, psoriatic arthritis, RA, JIA

    Enspryng (satralizumab)

    Covered when ALL of the following are met

    Enspryng initial coverage criteria: Patient has NMOSD; anti‑AQP4 antibody positive; at least one attack requiring rescue therapy in last year or two attacks in last two years; prescribed by or in consultation with a neurologist; progressive disease on a therapeutic trial of rituximab; EDSS ≤7.
    Enspryng continuation criteria: Documented positive clinical response to Enspryng evidenced by decreased relapse rate.
    Enspryng duration: Duration of approval: 12 months

    Entyvio SC (vedolizumab)

    Covered when ALL of the following general and diagnosis-specific criteria are met

    Entyvio general: Prescriber is a specialist or has consulted with a specialist.
    Entyvio Crohn's disease specific: Diagnosis of moderate to severe Crohn's disease; tried and failed or intolerant to adequate conventional therapy (e.g., steroids 7 days, immunomodulators ≥2 months); tried at least TWO of: adalimumab, Cimzia, infliximab, ustekinumab each ≥3 months.
    Entyvio ulcerative colitis specific: Diagnosis of moderate to severe ulcerative colitis; tried and failed or intolerant to adequate conventional therapy; tried at least TWO of: adalimumab, infliximab, Omvoh, Simponi, ustekinumab, Xeljanz/XR each ≥3 months.
    Entyvio dosing and benefit note: IV induction (week 0 and 2) covered under medical benefit; subsequent maintenance may be covered under medical or pharmacy benefit as SC.

    Eohilia (budesonide oral suspension)

    Covered when ALL of the following are met

    Eohilia diagnosis: Diagnosis of eosinophilic esophagitis confirmed by biopsy (≥15 intraepithelial eos/hpf).
    Eohilia prior therapies: Tried and failed dietary modification; one PPI for ≥2 months; one topical corticosteroid (e.g., fluticasone, budesonide) for ≥2 months.
    Eohilia age and prescriber: Patient is at least 1 year of age; prescribed by or in consultation with a gastroenterologist or allergist.
    Eohilia duration: Duration of approval: 12 weeks
    Eohilia combination therapy note:

    Epidiolex Initial Therapy

    Prior authorization required; initial authorization covered when ALL of the following are met:

    Epidiolex initial: Patient has a diagnosis of Lennox‑Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex; is using Epidiolex as adjunctive treatment for seizures associated with one of these diagnoses; patient is at least 1 year of age; and has tried and failed, or is intolerant/contraindicated to at least two generic anticonvulsants.

    Documentation must be submitted to Priority Health

    Evrysdi Initial and Continuation Therapy

    Evrysdi — Initial authorization covered when ALL of the following are met:

    Evrysdi genetic and clinical criteria: Prescribed by a neurologist or in consultation with a neurologist experienced in SMA; diagnosis of SMA; genetic testing confirming bi‑allelic SMN1 mutations (e.g., homozygous deletion, homozygous conversion, or compound heterozygous mutation); genetic testing confirming no more than 2 copies of SMN2 or symptom onset before 6 months of age; patient is symptomatic but not advanced SMA (no complete limb paralysis or permanent ventilator dependence); submit baseline MFM‑32, HINE, or other validated assessment tool.

    Evrysdi authorized only per FDA‑approved dosing; not for non‑5q SMA; not authorized for patients previously treated with Zolgensma or in combination with Spinraza

    Evrysdi continuation: Submit documentation showing maintenance or improvement via repeat MFM‑32, HINE or other validated assessments; for HINE show improvement in more motor milestone categories than worsening; for members >2 years show clinically significant improvement versus predicted natural history.

    Duration of approval: 6 months

    Fasenra Initial and Continuation Therapy

    Fasenra — Initial authorization covered when ALL of the following are met (condition-specific branches):

    Fasenra indication branches: Severe eosinophilic asthma: peripheral blood eosinophils >150 cells/mcL in past 12 months; tried ICS plus one additional controller; and at least one asthma exacerbation in prior year. OR EGPA: diagnosis confirmed by eosinophils >1000 cells/mcL or ≥10% leukocytes and tried systemic corticosteroid or immunosuppressive. OR HES: diagnosis without secondary cause; ≥2 HES flares in last 12 months OR eosinophils ≥1000 cells/mcL; stable on standard therapy.

    Continuation criteria require documented positive clinical response; duration 12 months; not covered in combination with other biologic therapy

    The plan limits accepted drug trials to drugs that the plan covers or prefers. For prior authorization and step‑therapy requirements, documented trials must be of plan‑covered or preferred medications; trials of non‑formulary or non‑preferred products will not satisfy prior therapy requirements used to qualify a patient for coverage.

    Adalimumab will not be covered in combination with another biologic drug. Coverage requires meeting all General and indication‑specific criteria; if criteria are unmet, the prescriber must provide a rationale for an exception or for use in a diagnosis not listed in the policy.

    Adbry (tralokinumab) is not covered in combination with other biologic drug therapy. Similarly, certain branded acute antimigraine agents (see acute migraine criteria) may not be used in combination with other branded acute agents; requests must meet the policy’s prior‑therapy and sequencing requirements to be eligible for coverage.

    Branded acute antimigraine agents are mutually exclusive for coverage: Ubrelvy, Nurtec, Zavzpret, and dihydroergotamine are not covered in combination with one another or any other branded acute treatment agent. In addition, Vyepti and Qulipta are not covered in combination with Botox or any other branded prophylactic agent; Vyepti dosing is limited to an initial 100 mg every 3 months with a one‑time 300 mg authorization considered only for inadequate response to 100 mg.

    Arcalyst will not be covered in combination with another biologic drug. Requests for Arcalyst must meet all General and diagnosis‑specific criteria for CAPS, DIRA, or recurrent pericarditis; if criteria are not met the prescriber must provide an explanation for an exception.

    Coding and Code Lists

    Product listings / delivery systemsmixed
    Repatha Pushtronex System 420 subcutaneous solution cartridgeProduct listing as affected
    Covered drug list (by product name as listed)NDCCovered
    Aimovigerenumab (pharmacy benefit)
    Ajovyfremanezumab (pharmacy benefit)
    Emgalitygalcanezumab (pharmacy benefit; includes 300 mg dose)
    Quliptaatogepant (pharmacy benefit, non-preferred)
    Vyeptieptinezumab (medical benefit, non-preferred)
    Sunlencalenacapavir (pharmacy benefit, preferred antiretroviral)
    Rukobiafostemsavir (pharmacy benefit, non-preferred antiretroviral)
    Trogarzoibalizumab (medical benefit, non-preferred antiretroviral)
    Affected Products (by name)NDC|Brand
    Camzyosmavacamten (preferred agent)
    Myqorzoaficamten (preferred agent)
    Carglumic AcidCarbaglu
    Caystonaztreonam inhalation solution (product listed)
    Cablivicaplacizumab (continuation criteria provided)
    Covered ICD-10 Diagnosis Codes (Cystic Fibrosis)ICD-10Covered
    E84.0Cystic fibrosis with pulmonary manifestations (as listed in document)
    E84.11Cystic fibrosis with meconium ileus
    E84.19Cystic fibrosis with intestinal manifestations
    E84.8Other cystic fibrosis
    E84.9Cystic fibrosis, unspecified
    Products Affectedmixed
    Enspryngsatralizumab
    Products Affectedmixed
    Entyvio PenVedolizumab subcutaneous pen
    Entyvio Subcutaneous Solution PenInjector 108 MG/0.68MLVedolizumab SC 108 mg/0.68 mL
    Products Affectedmixed
    Eohiliabudesonide oral suspension
    Products Affectedmixed
    Epidiolexcannabidiol
    Affected fentanyl lozenge products (strengths)NDC|mixedCovered
    1200 MCGfentaNYL Citrate Buccal Lozenge On A Handle 1200 MCG (product strength listed)
    200 MCGfentaNYL Citrate Buccal Lozenge On A Handle 200 MCG (product strength listed)
    Opioid morphine equivalent dose limit — 120 MEqD per day
    Opioid MEqD limit120 MEqD per day
    Exception requirementsRequests >120 MEqD require opioid treatment agreement, documented chronic pain diagnosis, documented taper attempt or rationale, routine validated pain/function assessments showing sustained improvement, trial of non-drug therapy in last 18 months (or contraindication), concurrent non-opioid medications unless contraindicated, documentation of safety when used with benzodiazepines/sedative-hypnotics/barbiturates, and naloxone education
    Additional utilization managementIndividual drug quantity limits, step therapy, and other utilization management may also apply
    Authorization durationWhen approved, treatment authorized up to 12 months

    Prior Authorization, Documentation & Submission Requirements

    Prior Authorization

    Prior authorization required for ADL-listed drugs and uses

    Prior authorization is required for drugs and uses specified on the Approved Drug List (ADL) and when drug use exceeds established coverage limits; drug-level criteria must be met before coverage and authorizations may be granted up to 12 months. For opioid dose exceptions above 120 MEqD/day, document an opioid treatment agreement, chronic pain diagnosis, taper attempt or rationale, routine validated pain/function assessments showing sustained improvement, trial of non-drug therapy within 18 months (or contraindication), concurrent non-opioid medications when appropriate, naloxone education, and safety documentation when combining with benzodiazepines/sedative-hypnotics/barbiturates. Individual drug quantity limits, step therapy, and other utilization management may also apply.

    • Opioid exceptions require documentation listed above when >120 MEqD/day.
    • Authorizations generally up to 12 months when approved.
    • Nonformulary/nonpreferred drugs do not satisfy step requirements unless otherwise allowed.
    Prior Authorization

    Acthar: confirm infantile spasms and age <2 years

    Continuation of Therapy — Renewal Requirements

    inv-333: Accrufer continuation

    Accrufer continuation of coverage requires:

    Accrufer continuation: Documentation of improvement in condition from baseline (e.g., improved tolerance and/or increased hemoglobin and ferritin levels).

    Authorization up to 12 months

    inv-334: Adbry continuation

    Continuation criteria for covered biologic therapy (Adbry):

    Clinical response required: Patient must have a positive clinical response (reduction in BSA affected, reduced pruritus and flares, improved ADL).

    Duration of approval: 12 months

    inv-335: Continuation therapy rules

    Continuation criteria per product group

    Step Therapy Requirements and Sequencing

    RequirementNotes
    Documented trial and therapeutic failure or intolerance/contraindication to the preferred medication(s)
    Trialed drugs must be plan‑covered or preferred (nonformulary/nonpreferred agents do not satisfy step requirements)
    Failures may be defined by laboratory measures or disease activity scores where specified; otherwise failure = lack of adequate therapeutic response when used adherently for an adequate period
    Prior authorization required and supporting clinical documentation must be submitted (use Employer Group & MyPriority Plans Pharmacy drug request form or ePA)
    Indication / Required prior therapyMinimum prior trial
    Crohn's disease — trial and failure or intolerance to adequate conventional therapy (e.g., steroids, azathioprine)
    Ulcerative colitis — trial and failure or intolerance to adequate conventional therapy (e.g., steroids, azathioprine)
    Plaque psoriasis — trial of one traditional non‑biologic systemic agent (e.g., methotrexate, cyclosporine, acitretin)
    Psoriatic arthritis / Rheumatoid arthritis — trial of at least one traditional non‑biologic systemic agent (examples listed)
    Hidradenitis suppurativa — trial of at least one other agent (e.g., intralesional/oral corticosteroids, systemic antibiotics, isotretinoin)
    StepDetails
    Preferred agent trial
    Try preferred PCSK9 inhibitor (Repatha) after a minimum continuous 8‑week trial of a high‑intensity statin (atorvastatin ≥40 mg or rosuvastatin ≥20 mg) with LDL‑C above goal
    Non‑preferred agent requirement
    For non‑preferred PCSK9 (Praluent): prescribing by cardiologist/endocrinologist/board‑certified lipidologist AND trial and failure or intolerance to preferred product plus additional statin therapy
    Required prior stepsNotes
    Trial of one triptan (e.g., sumatriptan, rizatriptan, naratriptan, zolmitriptan)
    Trial and failure or intolerance to preferred acute agent (Ubrelvy) required before non‑preferred branded acute agents
    Non‑preferred acute agent approvals generally require an additional triptan trial and documentation of intolerance or failure
    Preventive categoryStep requirement
    Migraine preventive — oral agents
    Patient must have tried any two oral preventive medications (examples: antidepressants, beta blockers, antiepileptics)
    Non‑preferred preventive biologics
    Non‑preferred agents require trial and failure/intolerance to Aimovig, Emgality, and Ajovy for 3 continuous months each (when applicable) before approval
    Arikayce requirementDocumentation / Prescriber
    Must be used as part of a multidrug background regimen and not as a single agent
    Failure to obtain a negative sputum culture after a minimum of 6 consecutive months of a multidrug regimen (e.g., macrolide, rifampin, ethambutol) is required
    Prescribed by or in consultation with an infectious disease specialist; sputum culture supporting MAC diagnosis must be submitted; continuation requires negative sputum culture within last 30 days for ongoing approval
    Bimzelx prior requirements (examples by indication)Required trials
    Plaque psoriasis — traditional systemic plus biologics
    Trial of one traditional non‑biologic systemic agent ≥3 months AND at least two biologics (e.g., adalimumab, Cosentyx, Enbrel, ustekinumab) each ≥3 months
    Hidradenitis suppurativa / Psoriatic arthritis / nr‑axSpA — biologic/systemic trials
    Prior use/failure of specified systemic and biologic agents per indication (each generally ≥3 months) and objective inflammation evidence where required for nr‑axSpA
    Required prior therapiesNotes
    Trial and failure or intolerance to midodrine
    Trial and failure or intolerance to fludrocortisone
    Other requirements: diagnosis of symptomatic neurogenic orthostatic hypotension, exclusion of other causes, trial of at least two nonpharmacologic interventions, and specialist prescribing/consultation
    Dupixent indicationRequired prior therapies
    Atopic dermatitis — topical therapy trial
    Trial of one medium‑to‑high potency topical corticosteroid for ≥3 months OR one topical calcineurin inhibitor for ≥3 months
    Eosinophilic esophagitis — conservative therapies before Dupixent
    Failed dietary modification, one PPI for ≥2 months, and one topical corticosteroid for ≥2 months (biopsy confirmation ≥15 eos/hpf required)
    Eohilia required prior stepsDuration / Prescriber
    Dietary modification — trial and failure
    Proton pump inhibitor (PPI) — trial for at least 2 months
    Topical corticosteroid (e.g., fluticasone or budesonide) — trial for at least 2 months
    Biopsy confirmation required (≥15 intraepithelial eos/hpf); patient at least 1 year of age; prescribed by or in consultation with gastroenterologist or allergist; duration of approval: 12 weeks

    Quantity & Dosing Limits

    Opioids (class-level) — 120 MEqD
    Opioids class-level MEqD limit120 MEqD per day
    ApplicationApplies to opioid medications subject to class-level quantity/dose limits; exceptions require documentation per policy
    Authorization durationWhen approved, treatment authorized up to 12 months
    Adbry (tralokinumab) — product-specific quantity/dosing notes referenced
    Adbry product noteAdbry (tralokinumab) requires specialist prescriber or specialist consultation and prior topical therapy trial(s) per policy
    Topical trial requirementOne medium-to-high potency topical corticosteroid ≥3 months OR one topical calcineurin inhibitor ≥3 months

    Site-of-Care and Biosimilar Notes

    Note
    Note

    Definitions and Background

    Prior authorization is required for drugs and uses specified on the Approved Drug List (ADL) and when drug use exceeds established coverage limits. When step therapy is required, a documented trial and therapeutic failure or an intolerance/contraindication to the plan’s preferred or covered medication(s) must be submitted; the plan will only accept trials of drugs that the plan covers or prefers — non‑formulary and non‑preferred drugs will not satisfy step‑therapy requirements. For off‑label or non‑listed uses not supported by FDA or recognized compendia, provide two published peer‑reviewed articles supporting the requested use. Following initial authorization, coverage may be discontinued for noncompliance or lack of demonstrable clinical benefit as described in the criteria.

    Definition — Prior authorization (brief)
    DefinitionPrior authorization: When a medication requires prior authorization, certain criteria must be met before it can be covered; may also apply when use exceeds ADL limits
    PurposeEnsures specified clinical criteria and documentation are provided before coverage is granted
    Submission methodsPrior authorization requires completion of the employer group pharmacy drug request form or electronic prior authorization (ePA)
    Policy Summary
    Payerpriority health
    PolicyEmployer Group Pharmacy Prior Authorization Criteria (partial)
    Policy CodePolicy N/A
    Change TypeAdministrative (no material clinical changes)
    Effective DateJul 20, 2026
    Last ReviewJul 20, 2026
    Next Review DateJul 20, 2026
    Key ActionComplete the Employer Group & MyPriority Plans Pharmacy (NonOncology) drug request form or submit an electronic prior authorization (ePA) when requesting prior authorization.
    SourceLink
    On This Page
    Coverage Criteria — Drug- and Indication-specific RulesCoding and Code ListsPrior Authorization, Documentation & Submission RequirementsContinuation of Therapy — Renewal RequirementsStep Therapy Requirements and SequencingQuantity & Dosing LimitsSite-of-Care and Biosimilar NotesDefinitions and Background
    Hidradenitis Suppurativa specific: Trial of at least one other agent for this condition (e.g., intralesional/oral corticosteroids, systemic antibiotics, isotretinoin).
    Plaque Psoriasis specific: Trial of one traditional non‑biologic systemic agent (e.g., methotrexate, cyclosporine, acitretin) for ≥3 months.>=3 months
    Psoriatic Arthritis specific: Trial of at least one traditional non‑biologic systemic agent (e.g., methotrexate, leflunomide, sulfasalazine, azathioprine) for ≥3 months.>=3 months
    Rheumatoid Arthritis specific: Trial of at least one traditional non‑biologic systemic agent (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) for ≥3 months.>=3 months
    Juvenile Idiopathic Arthritis specific: Trial of at least one other agent OR concurrent start with methotrexate/sulfasalazine/leflunomide OR aggressive disease as determined by prescriber.

    Duration of approval: 12 months; patients with negative cultures for 1 year will not be approved for continued treatment

    Continuation defined by renal response metrics

    Benlysta continuation (SLE): For continuation in SLE, patient must meet 3 of 6 response criteria: SELENA‑SLEDAI reduction ≥4 at 30 days; no disease progression on Physician Global Assessment; BILAG A=0 and B≤1; reduction in steroid dose; negative seroconversion or ≥20% autoantibody reduction; free of significant flares requiring steroid boost.3 of 6

    These are required to continue coverage for SLE

    Benlysta continuation (lupus nephritis): Continuation requires evidence of renal efficacy: urinary protein/creatinine ratio ≤0.7, eGFR no greater than 20% below pre‑flare or at least 60 mL/min/1.73m2, and no use of rescue therapy for treatment failure.UPCR <=0.7; eGFR criteria as stated

    These metrics define continued coverage for lupus nephritis

    Tried at least TWO of (adalimumab, Cosentyx, Enbrel, Xeljanz/XR) each ≥3 months.
    >=3 months
    nr-axSpA specifics: Objective signs of inflammation (elevated CRP and/or MRI sacroiliitis) AND tried at least TWO of (Cimzia, Cosentyx) each ≥3 months.
    Psoriatic arthritis specifics: Tried one traditional non‑biologic systemic ≥3 months AND tried at least TWO of (adalimumab, Cosentyx, Enbrel, Otezla/XR, ustekinumab, Xeljanz/XR) each ≥3 months.>=3 months
    Juvenile idiopathic arthritis: Patient has tried at least TWO of: adalimumab, Enbrel, tocilizumab, Xeljanz/XR each ≥3 months.>=3 months
    No specific induction criteria; eligible if General Initiation Criteria are met.
    nr-axSpA: Patient has objective signs of inflammation (elevated CRP and/or MRI sacroiliitis).
    Hidradenitis suppurativa: Patient has tried at least ONE other agent (e.g., intralesional/oral corticosteroids, systemic antibiotics, isotretinoin).
    see thresholds

    Duration of approval 12 months; continuation requires decreased symptoms/exacerbations vs baseline

    Dupixent for Prurigo Nodularis: Moderate to severe prurigo nodularis (WI‑NRS ≥7 and ≥20 nodular lesions); trial of one medium‑to‑high potency topical corticosteroid for ≥3 months AND one topical calcineurin inhibitor for ≥3 months.WI‑NRS >=7; >=20 nodules

    Continuation requires adherence and positive clinical response

    Dupixent for EoE: EoE confirmed by biopsy (≥15 eos/hpf); failed dietary modification; failed one PPI for ≥2 months; failed one topical corticosteroid for ≥2 months.>=15 eos/hpf

    Continuation requires histologic remission ≤6 eos/hpf and clinical response

    Dupixent for Chronic Urticaria: Patient is ≥12 years; tried two or more H1 antihistamines OR one H1 antihistamine plus one or more of H2 antihistamine, oral corticosteroid, or leukotriene modifier.age >=12
    Dupixent for Bullous Pemphigoid: Moderate to severe bullous pemphigoid (BPDAI ≥24 and weekly average Peak Pruritus NRS =4); trial of one medium‑to‑high potency topical corticosteroid for ≥3 months; one oral corticosteroid for ≥3 months; and one traditional non‑biologic systemic agent for ≥3 months.BPDAI >=24; Peak Pruritus NRS >=4

    Continuation requires adherence and positive clinical response

    Not covered in combination with biologic drug therapy
    High-intensity statin trial duration — minimum 8 weeks
    Required statin trial durationMinimum 8 weeks continuous trial of a high-intensity statin (atorvastatin ≥40 mg or rosuvastatin ≥20 mg)
    Indication contextApplies for hypercholesterolemia including ASCVD, HeFH, HoFH
    Combination exclusionNot to be used in combination with another PCSK9 inhibitor, Leqvio, Nexletol/Nexlizet
    Non-preferred agent requirementNon-preferred PCSK9 requires specialist prescribing and trial/failure or intolerance to preferred product plus additional statin
    Topical therapy trial duration (for atopic dermatitis) — minimum 3 months
    Topical therapy trial durationMinimum 3 months trial of a medium-to-high potency topical corticosteroid OR topical calcineurin inhibitor (tacrolimus or pimecrolimus)
    Prescriber requirementPrescriber must be a specialist or have consulted a specialist
    Continuation responseContinuation requires positive clinical response (reduced BSA, reduced pruritus/flares, improved ADLs); approval duration 12 months
    Age requirement for acute migraine agents — >= 18 years
    Minimum age>= 18 years
    IndicationApplies to acute antimigraine and cluster headache (Emgality) initial coverage
    Prior therapy requirementTrial of one triptan required before coverage of listed acute agents
    Monthly migraine days — >= 4
    Monthly migraine days threshold>= 4 migraine days per month
    Prior oral preventive trialsPatient must have tried any two oral preventive medications (examples: antidepressants, beta blockers, anti-epileptics)
    Non-preferred biologic requirementNon-preferred preventive agents require trial/failure of preferred biologics (Aimovig, Emgality, Ajovy) for 3 continuous months each when applicable
    Baseline HIV-1 RNA for treatment failure — >= 400 copies/mL
    Baseline HIV-1 RNA for treatment failure>= 400 copies/mL
    ContextApplies to heavily treatment-experienced HIV-1 adults with multidrug-resistant infection and documented failure of current ARV regimen
    Background regimen requirementRequested agent must be used with an optimized background regimen and documentation of sensitivity to at least one other ARV
    ANA titer — >= 1:80
    ANA titer threshold>= 1:80
    Use caseRequired for autoantibody-positive classification when assessing Benlysta eligibility for SLE or lupus nephritis
    Alternative antibody criterionAnti-dsDNA >= 30 IU/mL also qualifies as autoantibody-positive
    Anti-dsDNA level — >= 30 IU/mL
    Anti-dsDNA threshold>= 30 IU/mL
    Use caseRequired for autoantibody-positive classification for Benlysta eligibility in SLE or lupus nephritis
    Alternative antibody criterionANA titer >=1:80 also meets autoantibody-positive definition

    Acthar prior authorization requires documentation that the patient has infantile spasms and is less than 2 years of age. Approval duration for Acthar is 1 month with the specified dosing/taper schedule noted in the policy.

    • Must document diagnosis of infantile spasms and age <2 years.
    • Duration of approval: 1 month (dosing/taper instructions provided in policy).
    Prior Authorization

    Adalimumab: specialist prescriber + indication-specific therapy documentation

    Adalimumab prior authorization requires that the prescriber is a specialist or has consulted a specialist and that the patient meets the general criteria plus the indication‑specific prior-therapy requirements (e.g., adequate trials of conventional systemic therapies). Adalimumab is not covered in combination with another biologic.

    • Prescriber must be a specialist or document specialist consultation.
    • Provide evidence of required prior conventional therapy trials per treated diagnosis (examples: steroids, immunomodulators, non-biologic systemics).
    • Do not request concomitant use with another biologic (not covered).
    Prior Authorization

    Adbry: specialist prescriber and prior topical therapy trial(s)

    Adbry (tralokinumab) prior authorization requires the prescriber be a specialist or document specialist consultation and documentation that the patient has moderate to severe atopic dermatitis with prior adequate topical therapy trials. For initiation, the patient must have tried a medium‑to‑high potency topical corticosteroid or a topical calcineurin inhibitor for at least 3 months.

    • Prescriber is a specialist or has consulted a specialist for the condition.
    • Document moderate to severe atopic dermatitis.
    • Document trial of one medium‑to‑high potency topical corticosteroid OR one topical calcineurin inhibitor (tacrolimus or pimecrolimus) for ≥3 months.
    Prior Authorization

    PCSK9 inhibitors: high‑intensity statin trial ≥8 weeks before approval

    PCSK9 inhibitor prior authorization requires documentation of a continuous minimum 8‑week trial of a high‑intensity statin (atorvastatin ≥40 mg or rosuvastatin ≥20 mg) with LDL‑C remaining above goal. Non-preferred agents require specialist prescribing and trial/failure or intolerance to the preferred agent and additional statin therapy; PCSK9 inhibitors must not be used in combination with another PCSK9 inhibitor, Leqvio, Nexletol, or Nexlizet.

    • Document continuous high‑intensity statin trial ≥8 weeks with persistent LDL‑C above goal.
    • Non-preferred agent (Praluent) requires cardiologist/endocrinologist/lipidologist prescribing and trial/failure or intolerance to Repatha plus additional statin.
    • Do not combine with another PCSK9 inhibitor, Leqvio, Nexletol/Nexlizet.
    Prior Authorization

    Acute antimigraine agents: triptan trial and preferred-agent failure for non-preferred products

    Prior authorization for acute antimigraine agents requires a diagnosis of migraine, patient age ≥18, and documentation of a trial of one triptan. For non-preferred acute branded products, document trial and failure or intolerance to the preferred agent (Ubrelvy) and an additional triptan as required; duration of approval is typically 12 months.

    • Diagnosis of migraine with or without aura and age ≥18 years.
    • Document trial of one triptan (e.g., sumatriptan, rizatriptan).
    • For non-preferred products, document failure/intolerance to Ubrelvy and an additional triptan.
    Prior Authorization

    Products that require prior authorization (listed agents)

    Prior authorization is required for the listed products (examples include Aimovig, Ajovy, Emgality, Qulipta, Vyepti, Sunlenca, and Rukobia); follow the product‑specific criteria in the policy when submitting requests.

    • Complete product‑specific criteria per the policy for each listed agent.
    • Use the Employer Group & MyPriority Plans Pharmacy drug request form or ePA for submission.
    Billing Rule

    Submit PA using the Employer Group & MyPriority Plans Pharmacy drug request form or ePA

    Complete the Employer Group & MyPriority Plans Pharmacy (NonOncology) drug request form or submit via Electronic prior authorization (ePA) to initiate a prior authorization request; the policy provides the form link and requires this form for PA processing.

    • Use the Employer Group & MyPriority Plans Pharmacy (NonOncology) drug request form or ePA link provided in the policy.
    • Include all required clinical documentation as specified for the requested agent.
    Note

    Approval durations: initial ~6 months; continuation ~12 months (agent-specific exceptions apply)

    Initial approvals are generally for 6 months and continuation approvals are generally for 12 months; Arikayce continuation is an example with 12‑month continuation and some agents have specified shorter initial durations (e.g., Cablivi initial 30 days).

    • Typical durations: Initial = 6 months; Continuation = 12 months.
    • Follow drug-specific duration and quantity limits where provided (e.g., Cablivi initial 30 days / continuation 28 days).
    Prior Authorization

    Benlysta: age, autoantibody, and disease‑activity documentation required

    Benlysta prior authorization for active, autoantibody‑positive SLE requires the patient be ≥5 years old, be autoantibody‑positive (ANA ≥1:80 or anti‑dsDNA ≥30 IU/mL), and have active SLE demonstrated by SELENA‑SLEDAI >6 while on standard therapy for ≥12 weeks; similar antibody and age criteria apply for biopsy‑proven lupus nephritis with eGFR ≥30 mL/min/1.73m2.

    • Age ≥5 years and autoantibody‑positive (ANA ≥1:80 OR anti‑dsDNA ≥30 IU/mL).
    • Active SLE: SELENA‑SLEDAI >6 while on standard therapy for ≥12 weeks.
    • For lupus nephritis Class III–V: active renal disease requiring standard therapy and eGFR ≥30 mL/min/1.73m2.
    Prior Authorization

    Besremi: hematology/oncology prescriber and prior therapy requirements

    Besremi prior authorization requires diagnosis of high‑risk polycythemia vera, patient age ≥18, prescribing by or consultation with a hematologist/oncologist, trial and failure of hydroxyurea and pegylated interferon‑alfa 2a, ECOG 0–2, and eGFR ≥30 mL/min/1.73m2.

    • Document high‑risk polycythemia vera and supporting records.
    • Age ≥18 and hematology/oncology prescriber or documented consultation.
    • Document trial and failure of hydroxyurea AND pegylated interferon‑alfa 2a; ECOG 0–2; eGFR ≥30.
    Prior Authorization

    Cablivi: aTTP diagnosis and plasma exchange co‑administration required

    Cablivi prior authorization for acquired TTP requires documentation of thrombocytopenia and microangiopathic hemolysis, patient age ≥18, and that Cablivi will be administered in addition to plasma exchange and immunosuppressive therapy and continued for 30 days after plasma exchange.

    • Document aTTP diagnosis with thrombocytopenia and schistocytes/microangiopathic hemolysis.
    • Age ≥18 years.
    • Plan to administer Cablivi with plasma exchange plus immunosuppression and continue 30 days post‑exchange.
    Prior Authorization

    Cardiac myosin inhibitors: specialist prescribing, step therapy, and durations

    Prior authorization is required for cardiac myosin inhibitors (Camzyos, Myqorzo); initial approval is 6 months and continuation is 12 months. These agents must not be used in combination with one another and are to be prescribed by or in consultation with a cardiologist with required baseline eligibility.

    • Indication: symptomatic NYHA class II or III obstructive HCM, age ≥18, LVEF ≥55%, cardiologist involvement.
    • Document trial and failure/intolerance/contraindication to both beta blocker and calcium channel blocker prior to initiation.
    • Initial approval 6 months; continuation 12 months; Camzyos and Myqorzo not used together.
    Prior Authorization

    Carglumic acid (Carbaglu): NAGS deficiency documentation required

    Prior authorization for carglumic acid (Carbaglu) requires documentation of N‑acetylglutamate synthase (NAGS) deficiency with acute or chronic hyperammonemia; approvals may be granted for up to 12 months with required clinical documentation for continuation.

    • Document NAGS deficiency and hyperammonemia.
    • Provide clinical documentation for continuation; approval up to 12 months.
    Prior Authorization

    Cayston: CF diagnosis, age ≥7, Pseudomonas culture and susceptibility or prior tobramycin failure

    Cayston prior authorization requires documentation of cystic fibrosis (submit an approved CF ICD‑10 code within the last 12 months), patient age ≥7 years, a positive Pseudomonas aeruginosa airway culture, and either susceptibility showing aztreonam is the only effective inhaled antibiotic or prior tobramycin failure/intolerance/resistance.

    • Submit CF ICD‑10 code (E84.*) within last 12 months and age ≥7.
    • Provide positive sputum culture for Pseudomonas aeruginosa and susceptibility results or prior tobramycin failure/intolerance/resistance.
    • Continuation requires pulmonologist/CF specialist documentation of stabilization or improvement; dosing cycles 28 days on/28 days off.
    Prior Authorization

    Cholbam: diagnosis, VLCFA value, and baseline LFTs required

    Cholbam prior authorization requires documentation of a bile acid synthesis disorder due to single enzyme defects (SED) or a peroxisomal disorder, provision of a serum very long chain fatty acid (VLCFA) value, and baseline liver function tests.

    • Document diagnosis of SED or peroxisomal disorder.
    • Submit serum VLCFA result and baseline LFTs with the PA request.
    Prior Authorization

    Cibinqo: specialist prescriber, topical therapy trial(s), and prior systemic agent trials required

    Cibinqo prior authorization requires that the prescriber is a specialist or has consulted a specialist, documentation that the patient has moderate to severe atopic dermatitis, prior adequate topical therapy trial(s), and trials of at least two specified systemic/biologic agents as listed.

    • Specialist prescriber or documented specialist consultation required.
    • Document moderate to severe atopic dermatitis.
    • Provide prior topical therapy trial (medium‑to‑high potency steroid or topical calcineurin inhibitor ≥3 months) and trials of at least two systemic/biologic agents each ≥3 months.
    Documentation Required

    Specialist prescriber and indication‑specific prior therapy documentation required

    Prior authorization requires that the prescriber is a specialist or has consulted a specialist and that indication‑specific prior therapies and diagnostic criteria are documented per the policy for the requested drug and diagnosis.

    • Provide documentation of specialist involvement or consultation.
    • Include indication‑specific prior therapy trials and diagnostic evidence (labs, imaging, biopsies) as required by the drug's criteria.
    Prior Authorization

    CFTR modulators: submit CF ICD‑10 code and age‑appropriate formulation

    CFTR modulator prior authorization requires documentation of cystic fibrosis (submit an approved CF ICD‑10 code within the last 12 months) and that the requested formulation matches FDA‑labeled age for the member.

    • Submit CF ICD‑10 code (E84.0, E84.11, E84.19, E84.8, E84.9) within the last 12 months.
    • Requested formulation (granules, tablets) must match the FDA label for the member's age.
    Prior Authorization

    Diacomit: Dravet diagnosis, adjunctive with clobazam, prior valproate/clobazam failure required

    Diacomit (stiripentol) prior authorization requires a diagnosis of Dravet syndrome, patient age ≥2 years, use as adjunctive therapy with clobazam (not monotherapy), and documentation of prior trials and failure with valproate and clobazam.

    • Diagnosis of Dravet syndrome and age ≥2 years.
    • Use as adjunct to clobazam; Diacomit is not supported as monotherapy.
    • Document trial and failure with valproate and clobazam.
    Prior Authorization

    Droxidopa: nOH diagnosis, non‑pharmacologic trials, specialist consult, and prior midodrine/fludrocortisone trial

    Droxidopa prior authorization requires symptomatic neurogenic orthostatic hypotension due to specified causes with exclusion of other causes, trial of at least two non‑pharmacologic interventions, specialist prescribing or consultation (cardiology, neurology, or nephrology), and trial/failure or intolerance to midodrine and fludrocortisone; initial approval is 3 months with continuation requiring objective response documentation.

    • Document nOH diagnosis from listed causes and exclusion of other causes.
    • Document trial of ≥2 nonpharmacologic measures and trial/failure/intolerance to midodrine and fludrocortisone (≥30 days).
    • Prescribed by or in consultation with cardiologist, neurologist, or nephrologist; initial 3 months, continuation 6 months with documented benefit.
    Prior Authorization

    Dupixent: meet indication‑specific criteria and provide response data for continuation

    Dupixent prior authorization requires meeting the indication‑specific criteria listed (e.g., for atopic dermatitis document moderate to severe disease and prior topical therapy; for asthma document eosinophilic phenotype and prior controller therapy; for COPD, prurigo nodularis, EoE, chronic urticaria, and bullous pemphigoid meet the specific diagnostic and prior‑therapy requirements). Continuation requires demonstration of clinical response per indication.

    • Follow indication‑specific entry criteria (topical/systemic prior trials, objective measures such as eosinophil counts, spirometry, biopsy results, WI‑NRS, BPDAI, etc.).
    • Provide documentation of positive clinical response for continuation (examples per indication provided).
    • Dupixent is not covered in combination with other biologic drug therapy.
    Documentation Required

    PA submissions must document diagnosis, prior trials, and clinical benefit for continuation

    Prior authorization and duration: initial and continuation approvals require documented diagnostic criteria, required prior treatment trials, and demonstration of clinical benefit for continuation; standard duration of approval is 12 months unless otherwise specified.

    • Include diagnostic confirmation, prior therapy history, and objective measures as required.
    • Continuation approvals generally require evidence of clinical benefit and are typically 12 months.
    Prior Authorization

    Enspryng: submit PA form/ePA and AQP4 antibody documentation

    Enspryng prior authorization requires completion of the Employer Group & MyPriority Plans Pharmacy drug request form or ePA and submission of supporting documentation including neuromyelitis optica spectrum disorder diagnosis and anti‑AQP4 antibody positivity; duration of approval is 12 months.

    • Submit the Employer Group & MyPriority Plans Pharmacy drug request form or use ePA.
    • Provide NMOSD diagnosis and anti‑AQP4 antibody positivity documentation.
    • Duration of approval: 12 months; neurologist involvement and prior rituximab trial history required per criteria.
    Documentation Required

    Entyvio SC: complete PA form/ePA and provide prior therapy documentation

    Entyvio SC prior authorization requires completion of the Employer Group & MyPriority Plans Pharmacy drug request form or ePA and submission of required clinical history and prior therapy trials per the indication before coverage will be approved.

    • Complete the Employer Group & MyPriority Plans Pharmacy (NonOncology) drug request form or ePA.
    • Provide documentation of prior conventional therapy failure and trials of required biologics/agents (two agents for Crohn's/UC) as specified.
    Documentation Required

    Eohilia: biopsy confirmation and prior therapy documentation required

    Eohilia prior authorization requires completion of the Employer Group & MyPriority Plans Pharmacy drug request form or ePA and submission of biopsy confirmation (≥15 intraepithelial eosinophils/hpf) and documentation of prior therapy trials (dietary modification, PPI ≥2 months, topical corticosteroid ≥2 months).

    • Submit PA form or ePA and include biopsy showing ≥15 eos/hpf.
    • Document prior trials: dietary modification, one PPI ≥2 months, one topical corticosteroid ≥2 months.
    • Provide prescriber specialty (gastroenterologist or allergist).
    Prior Authorization

    Epidiolex: submit PA form/ePA and seizure diagnosis/prior anticonvulsant history

    Epidiolex prior authorization requires completion of the Employer Group & MyPriority Plans Pharmacy drug request form or ePA and supporting documentation of the qualifying diagnosis and prior anticonvulsant treatment history; initial coverage applies to Lennox‑Gastaut, Dravet, or tuberous sclerosis complex per the criteria.

    • Complete PA form or ePA for submission.
    • Document qualifying diagnosis and trial/failure or intolerance to at least two generic anticonvulsants.
    • Patient must be ≥1 year of age for coverage per policy.
    Prior Authorization

    Evrysdi: genetic confirmation and baseline motor function testing required

    Evrysdi prior authorization requires meeting the listed genetic and clinical criteria (prescriber neurologist, diagnosis of SMA with bi‑allelic SMN1 mutation, SMN2 copy number/onset limits, symptomatic but not advanced disease) and submission of baseline motor function assessment; duration of approval is 6 months for initial authorizations.

    • Provide genetic testing confirming bi‑allelic SMN1 mutations and SMN2 copy number/onset criteria.
    • Submit baseline motor function assessment (MFM‑32, HINE, or other validated tool).
    • Evrysdi authorized per FDA dosing only; initial duration 6 months; not authorized for prior Zolgensma recipients or in combination with Spinraza.
    Prior Authorization

    Fasenra: eosinophil counts and prior controller therapy documentation required

    Fasenra prior authorization requires condition‑specific criteria be met (e.g., severe eosinophilic asthma requires peripheral eosinophils >150 cells/mcL, prior controller therapy, and exacerbation history); provide peripheral eosinophil counts and prior controller/corticosteroid or immunosuppressive therapy documentation. Continuation requires demonstration of clinical response; duration typically 12 months.

    • Submit peripheral blood eosinophil counts and evidence of prior controller/ICS plus additional controller therapy for asthma.
    • Provide indication‑specific documentation (EGPA, HES) as required.
    • Continuation: document clinical response (reduced exacerbations, decreased steroid use) for ongoing authorization.
    Prior Authorization

    Fentanyl lozenge products require prior authorization

    Fentanyl citrate buccal lozenge products listed in the policy require prior authorization before coverage; submit the Employer Group & MyPriority Plans Pharmacy drug request form or ePA and include the clinical justification.

    • Affected strengths include the listed 200 mcg and 1200 mcg buccal lozenge products.
    • Complete PA form or ePA and provide clinical rationale for use.
    Step Therapy

    Step therapy: document trial and failure or intolerance to preferred agents

    When step therapy is required, the provider must document a trial and therapeutic failure or intolerance/contraindication to the preferred medication(s); failures must be of plan‑covered or preferred drugs to satisfy the requirement and the policy specifies required durations and examples per drug.

    • Document trials of preferred agents (drug names and minimum durations are specified in the policy).
    • Provide reasons for failure/intolerance or contraindication; nonformulary/nonpreferred drugs do not satisfy step requirements.
    Step Therapy

    Adalimumab preferred biosimilars listed — step to preferred agents

    Preferred adalimumab biosimilars are listed (e.g., adalimumab‑adaz, adalimumab‑adbm, adalimumab‑bwwd, adalimumab‑ryvk); requests should step to the preferred biosimilar/unbranded adalimumab agents where applicable.

    • Use preferred adalimumab biosimilar product names as listed when possible.
    • If requesting a non‑preferred adalimumab, provide clinical rationale and required prior therapy documentation.
    Step Therapy

    PCSK9 step: try Repatha before Praluent; non‑preferred needs trial/failure and specialist

    For PCSK9 inhibitors, the preferred agent (Repatha) should be tried before non‑preferred agents (Praluent); coverage of non‑preferred agents requires documentation of trial and failure or intolerance to the preferred product and additional statin therapy, and specialist prescribing.

    • Document trial/failure of Repatha prior to Praluent where required.
    • Non‑preferred agent requests should include cardiology/endocrinology/lipidology prescriber documentation.
    Step Therapy

    Acute migraine step: triptan trial and preferred agent (Ubrelvy) trial before non‑preferred

    For acute migraine treatment, patients should have tried a triptan and the preferred agent (Ubrelvy) prior to approval of non‑preferred acute branded agents; document the triptan trial and failure or intolerance to preferred agent where applicable.

    • Document trial of one triptan and trial/failure or intolerance to Ubrelvy for non‑preferred acute agents.
    • Duration of approval typically 12 months for approved acute agents.
    Step Therapy

    Migraine preventive step: try two oral preventives; non‑preferred biologics require preferred biologic failures

    For migraine preventive therapy, patients must have tried any two oral preventive medications; non‑preferred agents require failure/intolerance to the preferred biologic CGRPs (Aimovig, Emgality, Ajovy) for 3 continuous months each where specified.

    • Document trials of two oral preventive agents (examples provided in policy).
    • For non‑preferred preventive biologics, document 3 months each of Aimovig, Emgality, and Ajovy with inadequate response when required.
    Step Therapy

    Arikayce prerequisite: failed ≥6 months multidrug regimen and submit sputum culture

    Arikayce requires prior failure to achieve negative sputum cultures after a minimum of 6 months on a multidrug background regimen and must be used as part of a multidrug regimen; submit sputum culture supporting the MAC diagnosis to Priority Health.

    • Document failure to obtain negative sputum culture after ≥6 months on multidrug regimen (e.g., macrolide, rifampin, ethambutol).
    • Submit positive sputum culture and susceptibility data to Priority Health; Arikayce is not approved as single‑agent therapy.
    Step Therapy

    Bimzelx: document prior systemic and biologic therapy failures per indication

    Bimzelx requires prior use/failure of specified systemic and biologic agents per indication before approval (e.g., for plaque psoriasis one traditional non‑biologic systemic ≥3 months plus two biologics each ≥3 months); document the prior agents and durations.

    • Provide prior therapy history showing trials of required non‑biologic and biologic agents for the indicated durations.
    • Bimzelx will not be covered in combination with another biologic.
    CGRP migraine continuation: Demonstrate >50% reduction in monthly migraine days to continue migraine preventive biologic therapy.>50% reduction

    Applies to migraine headache requests

    Emgality cluster continuation: Demonstrate significant decrease in frequency/intensity and be in a current cluster period for Emgality continuation.
    Antiretroviral continuation: Clinically significant viral response and continued use of optimized background ARV regimen required for continuation of antiretroviral agents.

    inv-336: Continuation Therapy Rules

    Continuation therapy requirements and approval durations vary by drug and indication.

    General continuation durations: Initial approvals are typically 6 months; continuation approvals typically 12 months.Initial 6 months; Continuation 12 months

    (general statement)

    Arikayce continuation: Documentation of negative sputum culture within last 30 days, compliance, tolerability, and physician‑assessed response; duration 12 months; not continued if negative cultures for 1 year.negative sputum culture within 30 days

    Per ATS/IDSA guidance

    Benlysta continuation: SLE continuation requires meeting 3 of 6 response criteria; lupus nephritis continuation requires UPCR <=0.7 and eGFR criteria and no rescue therapy use.3 of 6 (SLE); UPCR <=0.7 (LN)

    Specific lab/score-based response metrics required

    inv-337: Benlysta continuation

    Benlysta continuation requires meeting specified response criteria

    Benlysta continuation: Meet 3 of 6 clinical/laboratory/assessment response criteria as listed in policy to continue Benlysta for SLE; lupus nephritis continuation uses renal thresholds.3 of 6

    Includes lupus nephritis‑specific laboratory thresholds for continuation

    inv-338: Besremi continuation

    Besremi continuation

    Besremi continuation: Patient has positive clinical response evidenced by disease stability or improvement.

    Duration 12 months

    inv-339: Cablivi continuation

    Cablivi continuation

    Cablivi continuation: Administration during plasma exchange and for 30 days post‑exchange, evidence of persistent disease (e.g., suppressed ADAMTS13); may extend up to 28 days.

    Quantity‑limit based continuation

    inv-340: Continuation Therapy

    Continuation requirements per drug

    Cablivi continuation: Patient received Cablivi with plasma exchange and immunosuppressive therapy during plasma exchange and for 30 days beyond last plasma exchange; signs of persistent underlying disease (e.g., suppressed ADAMTS13); treatment extended for max 28 days.28 days
    Camzyos continuation: Documentation of positive clinical response vs baseline and objective pVO2/NYHA improvements as specified; continuation approval duration 12 months.12 months
    Carglumic acid continuation: Clinical documentation showing disease stability or improvement must be provided; approval duration up to 12 months.12 months

    inv-341: Continuation therapy

    Continuation requirements by drug

    Cayston continuation: Continues to require treatment of Pseudomonas aeruginosa infection AND documentation of stabilization or improvement by pulmonologist or CF specialist.

    Duration: 12 months; dosing cycles 28 days on/28 days off

    Cholbam continuation: Weight increased by 10% or stable ≥50th percentile; ALT/AST <50 U/L or baseline reduced by 80%; total bilirubin ≤1 mg/dL; no evidence of cholestasis on liver biopsy.

    Duration: 12 months

    Cibinqo continuation: Positive clinical response (reduction in BSA, pruritus, flares, improvement in ADLs).

    inv-342: Continuation criteria (example)

    Continuation of coverage requirement (example provided):

    Clinical response for continuation: Patient must have a positive clinical response, e.g., reduction in body surface area (BSA) from baseline, reduction in pruritus severity and flares, and improvement in activities of daily living (ADL).

    inv-343: Continuation criteria

    Continuation approvals require documented clinical benefit:

    Crenessity continuation: Reduced daily glucocorticoid dose from baseline.
    Cresemba continuation: Disease stability or improvement.

    inv-344: Continuation Therapy

    Continuation requirements per drug

    Dalfampridine continuation: Maintain 85% adherence; documented functional improvement with ≥20% T25FW improvement; duration: 12 months.>=20% improvement
    Daybue continuation: Objective documentation of clinical improvement using specified tools; duration: continuation approvals as listed (3 months).

    inv-345: Droxidopa continuation

    Droxidopa continuation requirements

    Droxidopa continuation: Documentation of positive clinical response to droxidopa therapy; sustained decrease in dizziness since initiation; maintained increase in systolic and diastolic BP within 3 minutes of standing since initiation of therapy.

    Continuation approval duration: 6 months

    inv-346: Continuation Therapy — Dupixent and other biologics

    Continuation criteria vary by indication but require evidence of positive clinical response and adherence.

    Continuation requirements per indication: See continuation examples: AD—reduced BSA/pruritus; asthma—fewer exacerbations, decreased OCS use; CRSwNP—improved nasal symptoms; COPD—decrease in symptoms/exacerbations and continued LABA/LAMA with Dupixent; prurigo nodularis—adherence and WI‑NRS/nodule reduction; EoE—histologic remission <=6 eos/hpf and DSQ improvement; chronic urticaria—reduced symptoms; bullous pemphigoid—adherence and reduction in disease severity.varies by indication

    Duration of approval typically 12 months

    ContinuationContinuation requires positive clinical response; duration of approval 12 months; not to be used with other biologics
    Vyepti (eptinezumab) — 100 mg initial dosing; one-time 300 mg may be authorized for inadequate response
    Vyepti initial dosing100 mg initial dosing every 3 months
    One-time 300 mg allowanceA one-time authorization for 300 mg may be allowed for inadequate response to 100 mg
    Combination exclusionsVyepti not covered in combination with Botox or other branded prophylactic agents
    Cablivi (caplacizumab) — initial quantity limit (31)
    Cablivi initial quantity limitInitial quantity limit: 31 vials per 30 days (initial approval 30 days)
    Administration settingTo be administered in addition to plasma exchange and immunosuppressive therapy (hospital/infusion setting)
    Continuation quantity limitContinuation may be extended for a maximum of 28 days with quantity limit 28 vials per 28 days
    Cablivi (caplacizumab) — continuation — continuation quantity limit (28)
    Cablivi continuation quantity limitContinuation quantity limit: 28 vials per 28 days (max 28 days extension)
    Continuation requirementsPatient must have received Cablivi with plasma exchange and immunosuppression during plasma exchange and for 30 days beyond; evidence of persistent disease (e.g., suppressed ADAMTS13)
    Continuation approval durationContinuation approvals listed as 28 days per policy context
    Cayston — 28 days on, then 28 days off (treatment cycles)
    Cayston treatment cycle28 days on, then 28 days off (treatment cycles)
    Age requirementPatient must be at least 7 years of age for Cayston
    DocumentationSubmit CF ICD-10 code within last 12 months and positive Pseudomonas aeruginosa sputum culture with susceptibility or prior tobramycin failure/intolerance/resistance
    Definition — Acthar
    TermActhar Gel (corticotropin)
    Policy noteActhar requires diagnosis-specific age criteria (infantile spasms <2 years) per policy when applicable
    Not medically necessary usesActhar is not considered medically necessary for listed corticosteroid‑responsive conditions
    Definition — Adbry
    TermAdbry (tralokinumab)
    Indication summaryUsed for moderate to severe atopic dermatitis with prior topical therapy trial and specialist involvement required
    Continuation noteContinuation requires positive clinical response; duration 12 months; not to be used with other biologics
    Definition — Autoantibody-positive (ANA/anti-dsDNA thresholds)
    Autoantibody-positive definitionDefined as ANA titer >=1:80 OR anti-dsDNA >=30 IU/mL
    Use caseRequired for Benlysta eligibility for active SLE or biopsy-proven lupus nephritis
    Continuation contextContinuation requires meeting ≥3 of 6 specified clinical/lab response criteria for SLE
    Definition — Approved CF ICD-10 codes — E84.0, E84.11, E84.19, E84.8, E84.9
    Approved CF ICD-10 codesE84.0, E84.11, E84.19, E84.8, E84.9
    Documentation requirementA CF ICD-10 code within the last 12 months must be submitted for CFTR modulator PA
    Formulation matchingRequested formulation must match FDA label for age